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Selectins facilitate metastasis and the role of heparin in cancer 
Summary 
Metastatic disease is the primary cause of death for most cancer patients. Metastasis 
is facilitated by tumor cell interactions with the surrounding host cells. It is now clear 
that cell proliferation alone does not cause cancer, but the sustained proliferation in 
an environment consisting of inflammatory cells, growth factors and DNA-damaging 
agents promotes neoplastic progression. Causal interdependence between 
inflammation, innate immunity and cancer progression is widely accepted; however, 
many molecular and cellular mechanisms involved in metastasis have not been 
elucidated. Inflammatory cells were shown to promote tumor cell survival and 
migration. The tumor cell microenvironment consisting of platelets, leukocytes, 
endothelium and stromal cells actively participates in tumorigenesis and metastasis. 
Hematogenous carcinoma metastasis is supported by aggregated platelets and 
leukocytes, forming tumor cell emboli. The presence of tumor cells in circulation 
during hematogenous metastasis together with availability of vascular selectins is 
suggesting that selectin interactions with cancer cells may be implicated in 
metastasis (Figure). The physiological functions of selectins are well described in 
processes of initial tethering and rolling of leukocytes on endothelium which are 
supported by rapid and reversible interactions of selectins with their carbohydrate 
ligands. The participation of selectins in cancer progression is initiated by the findings 
that carcinomas, with enhanced selectin ligands expression on their mucins, confer 
to poor prognosis due to metastasis. We could show in several mouse models that 
early tumor cell-platelet interactions are mediated by P-selectin interactions with 
tumor cells, and this process can be blocked by heparin. The absence of P-selectin 
or its inhibition led to attenuation of metastasis. Reduction of metastasis was also 
observed in L-selectin deficient mice, indicating that leukocytes are directly 
implicated in the facilitation of this process. Finally, heparin treatment of cancer 
patients was shown to prolong their survival, which seems to be independent of 
anticoagulant activity. In parallel, heparin effectively attenuates metastasis in several 
pre-clinical models. The effect of heparin in this process remains under investigation, 
although observations from our laboratory strongly argue for primary inhibition of 
selectins to be responsible for attenuation of metastasis.  
 
 
 
Figure Potential inter-
actions between vascular 
selectins and their ligands 
carried either on tumor cells 
or endothelium during 
hematogenous metastasis. 
While multiple interactions 
are possible in vitro, their 
temporal and spatial 
occurrence in vivo remains 
to be determined (Borsig L. 
2004 News Physiol Sci
19:16-21). 
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In the enclosed work we studied and provided evidence for: a) the role of L-selectin 
in leukocytes participation on metastasis; b) contribution of selectin ligands to 
initiation of metastasis; c) characterization of heparin biological activities contributing 
to its anti-metastatic effect. We investigated how L-selectin facilitates establishment 
of pulmonary metastatic foci.  
 
An introduction into the area, including the current state of research, has been 
summarized on initial ten pages of the habilitation work. 
 
a) Role of L-selectin in facilitation of metastasis 
L-selectin Facilitation of Metastasis Involves Temporal Induction of Fut7-
Dependent Ligands at Sites of Tumor Cell Arrest. Läubli H, Stevenson JL, Varki 
A, Varki NM, Borsig L. 2006 Cancer Res 66:1536-42 
 
While L-selectin deficiency did not affect platelet aggregation or initial tumor cell 
embolization, the association of leukocytes with tumor cells was reduced, and tumor 
cell survival was diminished 24 hours later. Temporal inhibition of L-selectin by a 
function-blocking antibody reduced metastasis, which was synergistic with P-selectin 
deficiency in reducing metastasis. Analysis of leukocytes in the lung sections of 
injected mice revealed high presence of inflammatory leukocytes (granulocytes and 
monocytes) by the metastatic tumor cells, which was L-selectin dependent. These 
findings suggested that L-selectin mediates interaction of leukocytes with the tumor 
cell microenvironment, either with the thrombus itself or the surrounding endothelium. 
The endogenous L-selectin ligands were concomitantly induced adjacent to 
established intravascular tumor cell emboli, when leukocytes were also present. 
Indeed, an increase in the presence of leukocytes near the vascular tumor cells 
correlated with the enhanced expression of L-selectin ligands around the tumor cell 
embolus, indicative of locally activated endothelium. Metastasis was attenuated in 
mice missing these induced endogenous L-selectin ligands due to 
Fucosyltransferase-7 deficiency. Thus, L-selectin facilitation of metastasis 
progression involves leukocyte-endothelial interactions at sites of intravascular arrest 
supported by local induction of L-selectin ligands, thereby providing the first 
explanation for how leukocyte L-selectin facilitates tumor metastasis. 
 
b) Selectin ligands on carcinoma cells 
P-selectin mediates metastatic progression through binding to sulfatides on 
tumor cells. Garcia J, Calleawert N, Borsig L. 2007 Glycobiology 17:185-196. 
 
Carcinoma mucins are known selectin ligands and confers poor prognosis to cancer 
patients. We previously showed that mouse colon carcinoma cells (MC-38) carry P-
selectin ligands of non-mucin origin, which were not identified. The analysis of MC-38 
cells led to identification of glycosylceramides – sulfatides as the P-selectin ligand on 
these cells. Inhibition of sulfation almost completely abrogated P-selectin binding. 
Metabolic labeling of MC-38 cells revealed only a single band of a glycolipid 
recognized by P-selectin on HPTLC separated total lipid extracts. MALDI-TOF-TOF 
analysis of the purified sulfate-containing lipid fraction identified the selectin ligand to 
be a sulfated galactosylceramide (SM4 sulfatide). Modulation of glycolipid 
biosynthesis in MC-38 cells altered P-selectin binding, thereby confirming 
sulfoglycolipids to be major P-selectin ligands. Enzymatic removal of sulfation from 
the cell surface of MC-38 cells reduced P-selectin binding and resulted in attenuation 
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of metastasis. Overexpression of sulfatides has been observed in several human 
cancer such as renal and hepatocellular carcinomas. Therefore, we provided 
evidence that sulfatide (SM4) is a native selectin ligand recognized by P-selectin 
which mediates cell-cell interactions leading to metastasis. 
 
 
c) Blocking of selectin ligands by heparin leads to attenuation of metastasis 
P-selectin- and heparanase-dependent antimetastatic activity of non-
anticoagulant heparins. Hostettler N, Naggi A, Torri G, Ishai-Michaeli R, Casu B, 
Vlodavsky I, Borsig L. 2007 Faseb J Jun 8; [Epub ahead of print]. 
 
Heparin is known to efficiently attenuate metastasis in different tumor models, while 
its anti-metastatic effect remains open. We have shown in two mouse models that 
heparin is inhibiting experimental metastasis primarily by inhibition of P-selectin. 
When selectin blockade by heparin injection 6-18 hours after tumor cells led to 
reduced metastasis, there was no further effect in L-selectin-deficient animals. 
Heparin can apparently work primarily by blocking L-selectin. Characterization of 
modified non-anticoagulant species of heparin led to identification of derivatives 
specific for inhibition selectins or heparanase enzymatic activity. Selectin-specific 
heparin derivatives attenuated metastasis of MC-38 carcinoma, but heparanase-
specific derivatives had no effect. Heparin derivatives had no further effect on 
metastasis in mice deficient in both P- and L-selectin, indicating that selectins are the 
primary targets of heparin anti-metastatic activity. Selectin-specific and heparanase 
specific derivatives attenuated metastasis of B16-BL6 melanomas to a similar extent. 
These findings suggest that the potential of heparin to attenuate metastasis is 
primarily mediated through inhibition of selectin-mediated interactions and is 
completely independent of the anticoagulant activity. Based on observations in 
selectin deficient mice, heparins seem to affect early processes during metastasis, 
which are mediated predominantly by P- and L-selectin. 
 
Conclusion 
In these studies we characterize the role of selectins as facilitators of early cell-cell 
interactions contributing to metastasis. Selectin mediated interactions are required for 
initiation phase of this process as can be seen from temporally restricted blocking of 
L-selectin. Our study proposes L-selectin as one molecular link between recruitment 
of inflammatory leukocytes to the sites of tumor cell emboli and their potential to 
facilitate metastasis. Identification of heparin derivatives, with thoroughly 
characterized biological activities, have shown that inhibition of selectin is the primary 
mechanism how heparin contributes attenuation of cancer progression. Thus the 
described role of selectins by metastasis initiation together with the available 
evidence from preclinical studies and clinical trials strongly argue for the use of 
heparins as the first potential anti-metastatic treatment. 
